Sotera Health (SHC) Q1 2026 earnings review
Solid Core Masks Nelson Labs Margin Reversal
Sotera Health delivered a solid top-line quarter, with revenue accelerating 10.0% YoY driven by favorable Cobalt-60 harvest timing at Nordion and robust volume/pricing at Sterigenics. The bottom line reversed last year's loss, posting $26.6M in Net Income, while Adjusted EPS jumped 29% to $0.18. However, under the hood, the Nelson Labs segment remains a persistent drag. Segment income there plunged 11.5%, compressing margins significantly and contradicting the company's 2025 narrative of permanent operational stabilization in the mid-30% range. While management reaffirmed FY26 guidance and maintained a stable 3.2x net leverage ratio, the deteriorating profitability mix in Nelson Labs and heavy cash drag from legal settlements warrant close monitoring.
🐂 Bull Case
Nordion's revenue accelerated 29% YoY ($42.0M) while expanding segment margins by over 290 basis points to 56.4%. While lumpy due to harvest schedules, the segment continues to generate massive cash flow.
The core Sterigenics business showed stable, highly profitable growth (+9.7% YoY) driven by a healthy mix of underlying volume demand and sustained pricing power, defending its ~51.8% segment margin despite inflationary pressures.
🐻 Bear Case
Nelson Labs failed to grow (-0.7% YoY) and suffered an 11.5% drop in segment income. The mix-shift away from high-margin Expert Advisory Services continues to penalize the bottom line.
Operating Cash Flow nearly halved to $29M from $55M a year ago, dragged down heavily by a previously disclosed $34M payout for Illinois EO litigation settlements.
⚖️ Verdict: ⚪
Neutral. The core sterilization and isotope businesses are executing flawlessly, but Nelson Labs' margin compression and the ongoing cash drain from legal settlements prevent a fully bullish stance. FY26 guidance relies heavily on a Nelson Labs recovery that hasn't materialized yet.
Key Themes
Nelson Labs Margin Reversal Contradicts Narrative
Management stated Nelson Labs "came in as we outlined," yet the segment's operating margin compressed heavily from 31.4% in 25Q1 to 28.0% in 26Q1. Throughout 2025, management aggressively promoted that Nelson Labs had permanently stabilized in the "low-to-mid 30% range" (hitting 34.1% in 25Q3). This sudden deceleration back below 30% indicates structural volume/mix issues and casts doubt on the durability of the prior optimization initiatives.
Nordion Harvest Timing Accelerates Growth
Nordion was the quarter's absolute standout, delivering 25.8% constant currency revenue growth and 36.1% segment income growth. This acceleration is primarily driven by the timing of Cobalt-60 harvest schedules. While inherently lumpy quarter-to-quarter, the segment proved capable of significant operating leverage, dropping nearly all incremental revenue to the bottom line.
Sterigenics Stable Core Growth
Sterigenics generated $186.1M (+6.1% CC), successfully balancing favorable pricing actions with strong volume and mix. The segment's ability to hold a 51.8% margin amidst rising facility upgrade costs is a testament to its market dominance and the non-discretionary nature of medical device sterilization.
Technology Innovation: X-Ray Capacity Ramping
To satisfy customer demand for a full suite of sterilization modalities and alleviate capacity constraints, Sotera continues heavy CapEx investments (guided $175M-$225M in FY26) targeting the launch of a new X-ray facility slated for H2 2026. This allows the company to capture new MedTech volumes outside of traditional EO and Gamma constraints.
Macro: Tariffs Avoided via USMCA
While macroeconomic tariff concerns loom over the broader MedTech sector, Sotera remains largely insulated. The company leverages USMCA certifications for its Canadian Cobalt-60 supply to avoid cross-border penalties, giving it a strategic pricing advantage over competitors relying on alternative global supply chains.
Operating Cash Flow Squeezed by Legal Payouts
Operating Cash Flow decelerated severely to $29.4M (from $55.5M in 25Q1). This was directly impacted by the $34M cash outflow for previously agreed Illinois EO litigation settlements. Free Cash Flow for the quarter was deeply negative after factoring in $46.2M in CapEx, emphasizing how historical legal overhangs continue to hinder capital allocation today.
Persistent Legal Overhang Outside Illinois
While the Illinois EO litigation is largely settled, management's prior warnings regarding upcoming 2026-2027 trials (New Mexico AG trial in July 2026, and 83 personal injury claims in California starting 2027) demand investor caution. The defense costs ($9.9M this quarter alone) and settlement risks remain a structural headwind to Net Income.
Other KPIs
Accelerating. Grew 10.5% YoY (6.9% constant currency). The 48.1% margin reflects a 20 bps improvement YoY, showcasing the company's ability to drive operating leverage at Nordion and Sterigenics despite the weakness at Nelson Labs.
Stable. Down significantly from 3.7x in early 2025 and flat sequentially vs 25Q4. The company maintains over $900 million in available liquidity, allowing flexibility for debt paydown or strategic tuck-in M&A despite the heavy CapEx cycle.
Guidance
Stable. Management reaffirmed guidance, implying a 5.0% to 6.5% constant currency growth rate (plus ~100bps FX benefit). This assumes Nelson Labs returns to sequential growth in the back half of the year, which carries execution risk.
Stable. Reaffirmed 5.5% to 7.0% constant currency growth. The midpoint ($636.5M) implies an Adjusted EBITDA margin of roughly 51.2% for the full year, meaning profitability must sharply accelerate in Q2-Q4 compared to Q1's 48.1%.
Stable. Reaffirmed. The midpoint of $0.97 represents healthy ~13% YoY growth vs FY25's $0.86, driven by lower interest expense ($135M-$145M guided vs $156M in FY25) and top-line operating leverage.
Key Questions
Nelson Labs Margin Recovery
Nelson Labs segment margins contracted heavily to 28% this quarter. Is this entirely a function of the 'trailing comp challenges' in Expert Advisory Services mentioned in prior calls, and what specific sequential quarter does the model assume a return to the mid-30% range?
Nordion Harvest Normalization
Nordion grew 29% YoY driven by harvest timing. How much of this was a pull-forward from Q2/Q3, and should we model a sequential contraction for the segment in the upcoming quarter?
Capital Expenditure Timing
With Q1 CapEx at $46M, you are tracking toward the lower end of your $175M-$225M full-year guide. Is the spending ramp for the new 2026 X-ray facility heavily back-weighted, or are there delays in facility enhancements?